Truist Securities Maintains Buy on Roivant Sciences, Raises Price Target to $23
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas maintains a Buy rating on Roivant Sciences (NASDAQ:ROIV) and raises the price target from $19 to $23.
June 23, 2023 | 3:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on Roivant Sciences and raises the price target from $19 to $23.
The raised price target by Truist Securities analyst indicates a positive outlook for Roivant Sciences. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100